Temporal analysis of doxorubicin-induced cardiac toxicity and hypertrophy

Doxorubicin (DOX) is a potent anti-cancer drug that could induce cardiotoxicity in human bodies. To elucidate the underlying mechanisms behind DOX-induced toxicity, we conducted RNA sequencing on AC16, a well-established immortalized cardiac cell line, after treating it with DOX for 2, 4, and 6 days. We then performed RNA-Seq analysis on the obtained data. Our findings reveal significant alterations in key pathways within the AC16 cells treated with DOX, including disruptions in the MAPK cascade, apoptosis, inflammation, immune response, angiogenesis, and cardiac hypertrophy. To investigate the doxorubicin-induced cardiomyopathy, we performed RNA sequencing on the AC16 cells treated with DMEM, or 2, 4, and 6 days of doxorubicin.